Lexaria Bioscience (LEXX) Short Interest Ratio & Short Volume

Short interest is the volume of Lexaria Bioscience shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 257,200 shares of LEXX short. 2.29% of Lexaria Bioscience's shares are currently sold short. Learn More on Lexaria Bioscience's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.29% of Lexaria Bioscience's floating shares are currently sold short.

Lexaria Bioscience saw a decrease in short interest in April. As of April 30th, there was short interest totaling 257,200 shares, a decrease of 41.0% from the previous total of 435,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Lexaria Bioscience currently has issued a total of 12,890,000 shares. Some of Lexaria Bioscience's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lexaria Bioscience currently has a public float of 11,220,000 shares.

2.29% of Lexaria Bioscience's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lexaria Bioscience: NextCure, Inc. (0.53%), Unicycive Therapeutics, Inc. (2.13%), Cara Therapeutics, Inc. (5.62%), Sensei Biotherapeutics, Inc. (0.37%), Immuneering Co. (15.37%), Xilio Therapeutics, Inc. (5.24%), Eyenovia, Inc. (12.11%), Bolt Biotherapeutics, Inc. (8.80%), VYNE Therapeutics Inc. (0.68%), Rockwell Medical, Inc. (2.13%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling LEXX is an investing strategy that aims to generate trading profit from Lexaria Bioscience as its price is falling. LEXX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lexaria Bioscience occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LEXX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LEXX, twice per month. The most recent reporting period available is April, 30 2024.